Tumours often have areas of hypoxia, which renders cancer cells resistant to many therapies. Recently the anti-malarial drug Atovaquone has been shown to modify the oxygen consumption rate of cancer cells, reducing tumour hypoxia. Non-invasive mapping of tumour hypoxia would be particularly useful for translation of these preclinical findings into a clinical environment. Here, we tested the hypothesis that CEST MRI could be used to visualise changes in tumour hypoxia.
This abstract and the presentation materials are available to members only; a login is required.